Evidence map›Paper›PMID 25519252›Full record

SynthesisThe Cochrane database of systematic reviews2014

Cordyceps sinensis (a traditional Chinese medicine) for treating chronic kidney disease.

Hong Wei Zhang, Zhi Xiu Lin, Yuk Stewart Tung, Tze Hoi Kwan, Chun Keung Mok, Connie Leung, Lai Sum Chan

Open access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in The Cochrane database of systematic reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. FermentedRenal failure · 2024
    Pooled it
  2. Efficacy of traditional Chinese medicineFrontiers in medicine · 2024
    Pooled it
  3. Pooled it
  4. The efficacy ofRenal failure · 2026
    Article
  5. International journal of molecular sciences · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Impact ofFrontiers in pharmacology · 2025
    Article
  11. Observational
  12. Article
  13. Article
  14. Review
  15. Article
  16. Research Progress ofJournal of inflammation research · 2023
    Review
  17. Review
  18. Review
  19. Optimization ofHeliyon · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Hong Wei ZhangSchool of Chinese Medicine, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China.
Zhi Xiu Lin
Yuk Stewart Tung
Tze Hoi Kwan
Chun Keung Mok
Connie Leung
Lai Sum Chan
Chinese University of Hong Kong · CNTuen Mun Hospital · CNHong Kong Jockey Club · CNHospital Authority · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCordyceps sinensis (Cordyceps, Dong Chong Xia Cao), a herbal medicine also known as Chinese caterpillar fungus, is one of the most commonly used ingredients in traditional Chinese medicine for the treatment of people with chronic kidney disease (CKD).

objectivesThis review aimed to evaluate the therapeutic effects and potential adverse effects of Cordyceps sinensis for the treatment of people with CKD. SEARCH

methodsWe searched the Cochrane Renal Group's Specialised Register to 14 April 2014 through contact with the Trials' Search Co-ordinator using search terms relevant to this review. We also searched CINAHL, AMED, Current Controlled Trials, OpenSIGLE, and Chinese databases including CBM, CMCC, TCMLARS, Chinese Dissertation Database, CMAC and Index to Chinese Periodical Literature. SELECTION CRITERIA: Randomised and quasi-randomised trials comparing Cordyceps or its products with placebo, no treatment, or conventional treatment were considered for inclusion in the review. DATA COLLECTION AND ANALYSIS: Two authors independently assessed data quality and extracted data. Statistical analyses were performed using the random-effects model and the results expressed as risk ratio (RR) for dichotomous outcomes or mean difference (MD) for continuous data with 95% confidence intervals (CI). MAIN

resultsWe included 22 studies that involved 1746 participants. Among people with CKD who were not receiving dialysis, Cordyceps preparations were found to significantly decrease serum creatinine (14 studies, 987 participants): MD -60.76 μmol/L, 95% CI -85.82 to -35.71); increase creatinine clearance (6 studies, 362 participants): MD 9.22 mL/min, 95% CI 3.10 to 15.34) and reduce 24 hour proteinuria (4 studies, 211 participants: MD -0.15 g/24 h, 95% CI -0.24 to -0.05). However, suboptimal reporting and flawed methodological approaches meant that risk of bias was assessed as high in four studies and unclear in 18 studies, and hence, these results need to be interpreted with caution. AUTHORS'

conclusionsWe found that Cordyceps preparation, as an adjuvant therapy to conventional medicine, showed potential promise to decrease serum creatinine, increase creatine clearance, reduce proteinuria and alleviate CKD-associated complications, such as increased haemoglobin and serum albumin. However, definitive conclusions could not be made because of the low quality of evidence.

Indexed as

CordycepsCreatineCreatinineHumansPhytotherapyProteinuriaRandomized Controlled Trials as TopicRenal Insufficiency, ChronicCreatineCreatinine

Identifiers

PMID25519252
PMCPMC10632742
OpenAlexW1783794064

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.